SCHEMBL1542683

SCHEMBL1542683

COc1c(C(=O)Nc2cccc(NS(C)(=O)=O)c2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
CRBN Q96SW2 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
DHX9 Q08211 1/20 0.37
GAA P10253 2/20 0.37
ABL1 P00519 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLQ O75417 1/20 0.37
POLB P06746 2/20 0.36
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
MAPK14 Q16539 1/20 0.36
FYN P06241 1/20 0.36
TGFBR1 P36897 1/20 0.36
ACVR1 Q04771 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542202 0.88 CYP3A4 (0.60) CYP3A4MEN1KMT2AALDH1A1MAPK1
SCHEMBL1542438 0.88 CYP3A4 (0.61) CYP3A4ALDH1A1CRBNKDM4EPOLB
SCHEMBL1542760 0.87 CYP3A4 (0.55) CYP3A4NR1H4GAAABL1KDM4E
SCHEMBL1542824 0.87 CYP3A4 (0.52) CYP3A4MEN1KMT2AALDH1A1NR1H4
SCHEMBL1542874 0.85 CYP3A4 (0.51) CYP3A4NR1H4GAAABL1KDM4E
SCHEMBL2129460 0.84 CYP3A4 (0.59) CYP3A4MEN1KMT2AALDH1A1MAPK1
SCHEMBL1543035 0.83 CYP3A4 (0.61) CYP3A4MEN1KMT2AALDH1A1MAPK1
SCHEMBL1359735 0.83 CYP3A4 (0.46) CYP3A4ALDH1A1DHX9ABL1HPGD
SCHEMBL1542666 0.83 CYP3A4 (0.56) CYP3A4MEN1KMT2ANR1H4GAA
SCHEMBL2127612 0.83 CYP3A4 (0.58) CYP3A4MEN1KMT2AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885MEN1 4639/4885KMT2A 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.